News|Slideshows|October 15, 2019

Hepatitis C and Injection Drug Use: A True/False Quiz

Sample: True or false? Most new hepatitis C virus infections occur among people who inject drugs. Plus 4 more questions on hepatitis C and injection drug use.

Injection drug use is a common risk factor for hepatitis C virus (HCV) infection and while there are effective treatments available, injection drug-users often cannot afford the high costs. When left untreated, HCV can increase a patient’s risk for mortality. According to the National Institute on Drug Abuse, since 2012 there has been more deaths due to HCV vs 60 of the other reportable infectious disease combined. How much do you know about HCV in people who inject drugs (PWID)? Take our 5-question quiz below to find out.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Hepatitis C and Injection Drug Use: A True/False Quiz

Related Content

ACOG Releases New Guidance on HIV Screening and Prevention

FDA Accepts Cefiderocol sNDA for Pediatric Gram-Negative Infections

7 Drugs Approved for Primary Care: Q2 2026

FDA Clears First Generic Baloxavir for Influenza Treatment, Postexposure Prophylaxis

Cognitive Rehabilitation Linked to Functional Gains in Long COVID Trial

Latest CME

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Burst CME™: Transition from Pediatric to Adult Care in Sickle Cell Disease

Optimizing Lipid-Lowering Strategies for ASCVD Risk Reduction: Bridging the Gap in Treatment Intensification

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

27th Annual International Lung Cancer Congress®

Project ECHO®: Advancing Care in Metastatic TNBC Through PD-L1–Informed Novel Frontline ADC Strategies

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

Looking Beneath the Surface: Latest Updates in Identifying and Managing Hypercortisolism in Patients with Type 2 Diabetes

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

Minnesota Society of Clinical Oncology

South Carolina Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

Breaking Down the Rationale for Targeting TROP2 in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Washington State Medical Oncology Society

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

Optimizing Treatment for Biliary Tract Cancers

24th Annual International Congress on the Future of Breast Cancer® East

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Cross-Disease Integration of Immunotherapy Innovations

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Collaborating Across the Continuum™: The Pediatrician’s Vital Role in Multidisciplinary Management of Pediatric PAH

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Houston Hematology Satellite Symposia

Radioligand Therapy 101: The Science Behind the Strategy

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Arkansas Association of Cancer Professionals

North Carolina Oncology Association

2026 Carolina Neuromuscular Disease Summit

Pathways to Progress: RAS in GI Cancers (Spotlight CE Session)

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Tackling Barriers to Vaccine Uptake: Practical Strategies for Adult Immunization

Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum